儿童慢性肾脏病中钠-葡萄糖协同转运蛋白2抑制剂肾脏保护开发策略:2023年7月研讨会会议纪要
儿童慢性肾脏病(CKD)缺乏获批的延缓进展疗法。2023年7月由肾脏健康倡议与NephCure召开1.5天研讨会,多利益相关方参加,旨在阐明评估钠-葡萄糖协同转运蛋白2抑制剂(SGLT2is)在儿童CKD中应用的挑战与策略,讨论成人数据外推至儿童的可能性、试验设计可行性、终点、知识缺口与安全性,并提出推进评估的路径。
要点
- 儿童CKD目前仅用肾素-血管紧张素-醛固酮系统抑制剂等非特异性治疗,无获批延缓进展的疗法。
- SGLT2is在成人中可延缓估算肾小球滤过率下降和CKD进展,但儿童CKD的疗效、安全性和剂量数据缺乏。
- 研讨会提出推进SGLT2is治疗肾小球性和非肾小球性儿童CKD评估的路径,并明确剩余挑战和研究优先事项。
核心结论
- 研讨会提出推进SGLT2is作为治疗肾小球性和非肾小球性儿童CKD药物评估的路径,同时明确剩余挑战和研究优先事项。
研究设计与样本
- 2023年7月由肾脏健康倡议和NephCure召开1.5天研讨会,参加者包括监管机构、美国国立卫生研究院代表、试验研究者、临床医生和研究者、行业代表、患者倡导者和照护者。
主要发现
- SGLT2is在成人中已显示延缓估算肾小球滤过率下降速度和CKD进展的疗效。
- 儿童CKD患者使用肾素-血管紧张素-醛固酮系统抑制剂等非特异性治疗,但无获批的延缓儿童CKD进展的疗法。
- 缺乏告知SGLT2is在儿童CKD中疗效、安全性和剂量的临床数据。
- 研讨会聚焦支持成人与儿童CKD病程及预期治疗反应相似程度的数据,以及成人SGLT2is试验数据外推至儿童CKD患者的程度。
- 讨论还聚焦儿童CKD中SGLT2is的试验设计可行性、终点、知识缺口和安全性考虑。
临床怎么用
- 原文未据此给出推荐。
局限性
- 儿童CKD中SGLT2is的疗效、安全性和剂量数据缺乏。
- 需明确成人数据外推至儿童CKD患者的程度。
- 研讨会识别了剩余挑战和研究优先事项。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pediatric patients with chronic kidney disease (CKD) are treated with nonspecific therapies such as renin-angiotensin-aldosterone system inhibitors; however, there are no approved therapies to slow the progression of pediatric CKD across its diverse etiologies. Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have demonstrated efficacy in slowing the rate of decline in estimated glomerular filtration rate and CKD progression in adults. These therapies hold the promise of similar clinical benefit for pediatric patients with CKD by potentially delaying progression to kidney failure. However, clinical data informing the efficacy, safety, and dosing of these products in pediatric patients with CKD are lacking. To address this issue, a 1.5-day workshop was convened by the Kidney Health Initiative and NephCure, with participation from stakeholders that included regulators, National Institutes of Health representatives, trialists, clinicians and investigators, industry representatives, patient advocates, and caregivers. The goal of the workshop was to elucidate the challenges and strategize approaches to evaluate the use of SGLT2is in pediatric patients with CKD. To this end, presentations and discussions at the workshop focused on the data supporting the degree to which the course of CKD and expected treatment responses between adult and pediatric populations with CKD are similar, and hence, the degree to which, if any, data from the trials of SGLT2is in adults could be extrapolated to pediatric patients with CKD. Discussions also focused on trial design feasibility, end points, gaps in knowledge, and safety considerations for SGLT2is in pediatric CKD. The workshop proposed pathways to advance the evaluation of SGLT2is as therapeutic agents to treat glomerular and nonglomerular pediatric CKD while identifying remaining challenges and research priorities.
引用
- Smoyer WE, Gillespie BS, Oni L, et al. Strategies for the development of sodium-glucose cotransporter-2 inhibitors for kidney protection in pediatric chronic kidney disease: proceedings of a workshop meeting in July 2023. Kidney Int. 2025. PMID: 41005567. doi:10.1016/j.kint.2025.09.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。